Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
5-ASA also inhibits the growth of DLD-1, a COX-deficient CRC cell line, thus suggesting that the anti-proliferative effect of 5-ASA on CRC cells is not strictly dependent on the inhibition of COX-2/PGE2.
|
17981262 |
2008 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
COX regression analysis indicated that low expression of CIAPIN1, cancer stage of > pT1, distant organ metastasis (pM1), regional lymph node metastasis (> pN1) and local recurrence (yes) were independent, poor prognostic factors of CRC (P = 0.012, P = 0.032, P <0.001, P <0.001, P <0.001 respectively).
|
20815902 |
2010 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
COX regression analysis and Kaplan-Meier survival analysis were performed to determine the relationship between RAR<i>β</i> expression and CRC prognosis.
|
30944670 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased expression of carbonic anhydrase-related protein (CA-RP) VIII has previously been shown in colorectal carcinoma.
|
17219437 |
2007 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been demonstrated that the chronic use of non-steroidal anti-inflammatory drugs (COX inhibitors) partially protects patients from colorectal cancer (CRC) development and progression but induces severe cardiovascular side effects.
|
20717114 |
2010 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is envisaged that dual inhibition of 5-LOX/COX could be the most promising therapeutic option for the treatment of colorectal cancer in humans.
|
26997150 |
2016 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Milk fat globule-epidermal growth factor (EGF)-factor VIII (MFG-E8) was found to be highly expressed in a variety of cancers.However its role in CRC is unclear.
|
28923329 |
2017 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nonsteroidal antiinflammatory drugs (NSAIDs) are postulated to protect against colorectal cancer and adenomas at least in part by a cyclooxygenase (COX-mediated mechanism.
|
15807932 |
2005 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies have shown that COX-2-derived PGE2 promotes CRC progression, and both nonselective COX inhibitors (NSAIDs) and selective COX-2 inhibitors (such as glucocorticoids) reduce the number and size of colonic adenomas.
|
19307727 |
2009 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that CA-RP VIII plays a role in the process of invasion in colorectal cancer.
|
12950015 |
2003 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To cast light on the role(s) of COX enzymes in the development and progression of colorectal cancers and to determine the incidence of COX-2 overexpression, the expression levels of COX-1 and COX-2 proteins using Western blot analysis in tumor tissues and adjacent normal tissues obtained from 44 Thai patients with colorectal cancer.
|
15075004 |
2004 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancer.
|
30626261 |
2019 |